TECH Stock Forecast: Bio-Techne Corp. Price Predictions for 2026-2027

Last close, 20 Nov 2026
$73
−0.01% on the day

The 13 Wall Street analysts covering Bio-Techne Corp. hold a median 12-month price target of $73 — +0.4% from the last close. Ticker Nerd's systematic factor model, run across ~4,300 US stocks, ranks it 96 of 100 as at 21 Nov 2026 — among the strongest tenth. Here, the model and the Street point the same way.

Market cap
$11.4B
Ticker Nerd rank
96/ 100
Median analyst target
$73
Analysts covering
13
Revenue$321.2M+1.3% y/y
Operating income$95.0M
Net income$54.6M
Free cash flow$86.9M
Quarterly, 8 quarters to 30 June 2026 · latest quarter's figure shown
Total return, dividends reinvested
1W
−0.1%
1M
+0.3%
YTD
+24.2%
1Y
+24.4%
From 52W high
−0.1%
From 52W low
+68.5%
$43
$73
52-week range, adjusted closes · the dot is the last close
Ticker Nerd rank

One number for the whole business

Consensus tells you what everyone already believes. The model scores Bio-Techne Corp. on its factor families — the same systematic rank behind the Ticker Nerd portfolio.

Where the model ranks itAs at 21 Nov 2026
96/ 100

Percentile across ~4,300 US stocks on Ticker Nerd’s systematic factor model. Higher is better. How the model is built and tested

Volatility
92
Momentum
92
Issuance
87
Value
82
Accruals
80
Quality
78
Revisions
70
Growth
69

Volatility (92): The share price has been relatively steady.

Growth (69): Sales and profits are flat, shrinking, or growing more slowly than they were.

Built and run by Aslam Ghouse, an ex-Goldman Sachs systematic trader with 15+ years in markets.

Wall Street

TECH stock forecast 2026-2027: analyst price targets & predictions

The bullish and bearish analyst opinions on TECH, reported as data — targets and ratings, the market's view beside the model's.

Share price and the analyst range, 12 monthsAdjusted close, US dollars
$40$45$50$55$60$65$70$75Jan 26Apr 26Jul 26Oct 26TECHHigh $73Median $73Low $50

Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.

Data provided by Twelve Data

What Wall Street says13 analysts
0
Buy
12
Hold
1
Sell
$50
Low
$73
Median
$73
High

The green dot is the last close — the median target sits +0.4% from it.

Recent analyst actionsNewest first
DateFirmActionRatingTarget
13 Aug 2026Wells FargoDowngradeEqual-Weight$62 → $73
9 July 2026RBC CapitalDowngradeSector Perform$62 → $73
30 June 2026BenchmarkDowngradeHold—
30 June 2026TD CowenDowngradeHold—
29 June 2026CitigroupDowngradeNeutral—
26 June 2026BairdMaintainsNeutral—
26 June 2026Stephens & Co.DowngradeEqual-Weight—
26 June 2026William BlairDowngradeMarket Perform—
11 June 2026Piper SandlerInitiatesNeutral—
15 May 2026RBC CapitalReinstatesOutperform$62
7 May 2026CitigroupMaintainsBuy—
7 May 2026Evercore ISI GroupMaintainsIn-Line—
7 May 2026Wells FargoMaintainsOverweight—
6 Apr 2026Evercore ISI GroupMaintainsIn-Line—
6 Feb 2026Wells FargoMaintainsOverweight—
5 Feb 2026CitigroupMaintainsBuy—
5 Feb 2026Evercore ISI GroupMaintainsIn-Line—
5 Feb 2026StifelMaintainsHold—
5 Feb 2026TD CowenMaintainsBuy—
5 Feb 2026UBSMaintainsBuy—

Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.

Wall Street targets run 12 to 18 months out. No analyst publishes a 2030 price target for TECH.

Market Radar

This page is one stock. Monday covers all of them.

TECH appears in the Radar on the weeks it earns a place.

  • Market Radar, every Monday: the week's biggest rank moves across ~4,300 US stocks, and the reason for each.
  • The AI build-out map, free: every AI company we track on one page, with the model's Top picks in all four parts.

Free. Unsubscribe any time. Privacy

The AI build-out map
PDF
  • AI cloud capacity

    MSFTAMZNGOOGLORCL

  • AI chips

    NVDAAVGOAMDMU

  • AI networking and servers

    ANETDELLLITECRDO

  • Data centre power

    VRTCEGGEVVST

Performance

TECH vs the S&P 500

Both lines are total return — dividends reinvested — so the comparison is honest on both sides.

Over the twelve months to 20 Nov 2026, Bio-Techne Corp. returned +24.4% against +6.9% for the S&P 500, dividends included.

TECH vs S&P 500, last 12 monthsTotal return, rebased to 100
708090100110120130Jan 26Apr 26Jul 26Oct 26TECHS&P 500

Download this chart as an image — free to reuse; link this page as the source.

Data provided by Twelve Data

Estimates

TECH analyst estimate revisions

Not the forecast itself — the direction analysts are revising it. Revision direction is one of the model's factor families.

Which way the estimates are movingThis fiscal year
EPS revision, 90 days
−0.7%
Analysts raising
0
Analysts cutting
1
Fundamentals

Financials

A margin means little on its own. Each bar marks where the figure sits across the whole US universe we score.

Valuation
Trailing P/E
66.7×

Cheaper than 12% of US stocks

Price / sales
9.3×

Cheaper than 12% of US stocks

Price / book
5.3×

Cheaper than 17% of US stocks

EV / EBITDA
34.9×

Cheaper than 9% of US stocks

Growth & margins
Revenue growth (YoY)
4.6%

Higher than 39% of US stocks

Earnings growth (YoY)
−25.9%

Higher than 18% of US stocks

Gross margin
65.8%

Higher than 79% of US stocks

Operating margin
21.7%

Higher than 81% of US stocks

Net margin
14.0%

Higher than 75% of US stocks

Returns & dividend
Return on equity
8.3%

Higher than 58% of US stocks

Return on assets
6.5%

Higher than 82% of US stocks

Dividend yield
0.4%

Higher than 7% of US dividend payers

Bars mark the percentile across the ~4,300 US stocks Ticker Nerd covers, among those reporting the figure.

Statistics

Key statistics

The headline figures, each with its date. Every row carries its own link — cite it straight from here.

  • Bio-Techne Corp. has a market value of $11.4B and an enterprise value of $11.4B.

  • Revenue in the twelve months to 30 June 2026: $1.2B. The latest quarter grew 1.3% year on year.

  • Net income over the same four quarters: $181.9M, a 15.0% net margin.

  • Diluted earnings per share, trailing twelve months: $1.15.

  • Free cash flow in the twelve months to 30 June 2026: $263.2M.

  • Bio-Techne Corp. spent $41.7M on share buybacks and $49.9M on dividends in the twelve months to 30 June 2026.

  • Shares outstanding: 156.1M.

  • Trailing P/E: 66.7×; forward P/E: 31.5× — the forward figure prices analyst consensus estimates, not reported earnings.

  • Forward dividend yield: 0.44%, paying out 29% of earnings.

  • Bio-Techne Corp. employs 3,000 people — $405K of revenue per employee.

Statement figures: company filings via Twelve Data, four quarters to 30 June 2026 · market figures as at 20 Nov 2026

Data provided by Twelve Data

Peers

TECH and its peers

The nearest names by industry and size, scored by the same model — like for like.

Its peer group, ranked by the same modelBiotechnology
CompanyMarket capTKN rank
TECHBio-Techne Corp.$11.4B96
BMRNBioMarin Pharmaceutical, Inc.$11.7B51
HALOHalozyme Therapeutics, Inc.$10.4B96
TGTXTG Therapeutics, Inc.$10.1B78
KYMRKymera Therapeutics, Inc.$9.6B65
KRYSKrystal Biotech, Inc.$9.1B83
JAZZJazz Pharmaceuticals Plc$14.4B95

Take a look at TECH’s peer groups, ranked by the model: healthcare stocks · biotech stocks.

Look up any of the roughly 4,300 stocks we score.

The rank is the raw material. Whether the rules would actually own Bio-Techne Corp. — and when they’d sell — is the membership. See the Ticker Nerd 20 →

FAQ

Questions about TECH

What is the TECH stock price forecast for 2026-2027?

The 13 Wall Street analysts covering Bio-Techne Corp. have a median 12-month price target of $73, with estimates ranging from $50 to $73. These are third-party analyst estimates, not Ticker Nerd forecasts, and they are frequently wrong.

Is TECH stock a buy right now?

Of the 13 analysts covering Bio-Techne Corp., 0 rate it a Buy, 12 a Hold and 1 a Sell. Ticker Nerd's systematic factor model ranks Bio-Techne Corp. 96 out of 100 across roughly 4,300 US stocks as at 21 Nov 2026. None of this is personal advice — it does not consider your circumstances.

How does Ticker Nerd's model rank TECH?

As at 21 Nov 2026, Bio-Techne Corp. ranks 96 out of 100 on Ticker Nerd's systematic factor model — a percentile across roughly 4,300 US stocks, built from its factor families. Its strongest factor family is Volatility (92 of 100).

Will TECH stock go up?

No one can know that. What the data says: the median 12-month target from 13 analysts implies +0.4% from the last close, and Ticker Nerd's factor model ranks Bio-Techne Corp. 96 out of 100 as at 21 Nov 2026. Analyst targets are third-party estimates and frequently wrong; none of this is personal advice.

What is the TECH stock forecast for 2030?

No analyst covering Bio-Techne Corp. publishes a 2030 price target — Wall Street targets run 12 to 18 months out. Sites quoting a 2030 price for TECH are extrapolating price history, which says nothing about the business. The furthest attributed numbers are the current analyst targets: $50 to $73 over the next 12 months.

How has TECH stock performed over the past year?

Bio-Techne Corp. returned +24.4% over the 12 months to 20 Nov 2026, with dividends reinvested. Past performance does not indicate future returns.

What does Bio-Techne Corp. do?

Bio-Techne Corp. is a global life sciences company that develops, manufactures, and sells reagents, analytical instruments, and precision diagnostics for research, diagnostic, and bioprocessing applications. Its portfolio supports workflows across basic research, translational science, and clinical decision-making, serving customers in academic laboratories, biotechnology and pharmaceutical development, and diagnostic settings.

Company

About Bio-Techne Corp.

Bio-Techne Corp. is a global life sciences company that develops, manufactures, and sells reagents, analytical instruments, and precision diagnostics for research, diagnostic, and bioprocessing applications. Its portfolio supports workflows across basic research, translational science, and clinical decision-making, serving customers in academic laboratories, biotechnology and pharmaceutical development, and diagnostic settings. The company’s products include proteins, antibodies, immunoassays, ELISA kits, molecular diagnostics, spatial biology tools, and specialized instruments used to detect, measure, and analyze biological activity. Bio-Techne also provides custom services such as antibody development, protein degradation solutions, gene engineering, and cell and gene therapy-related services. Through its Protein Sciences and Diagnostics and Spatial Biology businesses, Bio-Techne plays an important role in enabling scientific discovery, biomarker analysis, and laboratory testing across the global healthcare and life sciences market.

CEO Mr. Kim Kelderman · 3,000 employees · United States · https://www.bio-techne.com